IL269315B2 - Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker - Google Patents

Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Info

Publication number
IL269315B2
IL269315B2 IL269315A IL26931519A IL269315B2 IL 269315 B2 IL269315 B2 IL 269315B2 IL 269315 A IL269315 A IL 269315A IL 26931519 A IL26931519 A IL 26931519A IL 269315 B2 IL269315 B2 IL 269315B2
Authority
IL
Israel
Prior art keywords
subject
cells
marker
cell
ctcs
Prior art date
Application number
IL269315A
Other languages
English (en)
Hebrew (he)
Other versions
IL269315A (en
IL269315B1 (en
Inventor
Cedric Blanpain
Panagiota Sotiropoulou
Ievgenia Pastushenko
Original Assignee
Univ Bruxelles
Cedric Blanpain
Panagiota Sotiropoulou
Ievgenia Pastushenko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles, Cedric Blanpain, Panagiota Sotiropoulou, Ievgenia Pastushenko filed Critical Univ Bruxelles
Publication of IL269315A publication Critical patent/IL269315A/en
Publication of IL269315B1 publication Critical patent/IL269315B1/en
Publication of IL269315B2 publication Critical patent/IL269315B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL269315A 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker IL269315B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161411 2017-03-16
PCT/EP2018/056760 WO2018167312A1 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Publications (3)

Publication Number Publication Date
IL269315A IL269315A (en) 2019-11-28
IL269315B1 IL269315B1 (en) 2025-01-01
IL269315B2 true IL269315B2 (en) 2025-05-01

Family

ID=58387669

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269315A IL269315B2 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Country Status (8)

Country Link
US (2) US12123877B2 (enExample)
EP (2) EP4235179B1 (enExample)
JP (1) JP7278595B2 (enExample)
KR (1) KR102583603B1 (enExample)
AU (1) AU2018235021B2 (enExample)
CA (1) CA3054915A1 (enExample)
IL (1) IL269315B2 (enExample)
WO (1) WO2018167312A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019202788A1 (de) * 2019-03-01 2020-09-03 Robert Bosch Gmbh Verfahren zum Zählen von Zelltypen oder Zellmarkern in einer Probe, insbesondere in einer Blutprobe
JP2020144054A (ja) * 2019-03-07 2020-09-10 学校法人昭和大学 末梢血循環癌細胞の検出方法及び検出装置
KR102654518B1 (ko) * 2020-05-26 2024-04-04 가톨릭대학교 산학협력단 Lsp1 결핍 t 세포
CN113009135B (zh) * 2021-02-19 2024-04-02 山东省大健康精准医疗产业技术研究院 一种检测cd47的管式磁微粒化学发光免疫定量试剂盒及其制备方法与应用
CA3233047A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130737A1 (en) * 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
EP2199798A1 (en) * 2008-12-18 2010-06-23 Universite Libre De Bruxelles Diagnostic method and kit of circulating tumor cells
WO2013148450A1 (en) * 2012-03-30 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Use of jam-a in diagnosing and treating leukemia
WO2014120265A1 (en) * 2013-02-02 2014-08-07 Duke University Method of isolating circulating tumor cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US8980568B2 (en) * 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
AU2004286307A1 (en) * 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2007056049A2 (en) 2005-11-02 2007-05-18 The Regents Of The University Of Michigan Molecular profiling of cancer
JP2007181462A (ja) 2005-12-30 2007-07-19 Centocor Inc 細胞の表現型を測定する方法
GB0808413D0 (en) 2008-05-09 2008-06-18 Univ Nottingham Stabilisation of blood cell conjugates
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
AU2014364520B2 (en) 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
CA2975726C (en) 2015-01-21 2022-03-15 Agency For Science, Technology And Research An isolated population of cell clusters and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130737A1 (en) * 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
EP2199798A1 (en) * 2008-12-18 2010-06-23 Universite Libre De Bruxelles Diagnostic method and kit of circulating tumor cells
WO2013148450A1 (en) * 2012-03-30 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Use of jam-a in diagnosing and treating leukemia
WO2014120265A1 (en) * 2013-02-02 2014-08-07 Duke University Method of isolating circulating tumor cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUSTIN D. LATHIA ET AL, " HIGH-THROUGHPUT FLOW CYTOMETRY SCREENING REVEALS A ROLE FOR JUNCTIONAL ADHESION MOLECULE A AS A CANCER STEM CELL MAINTENANCE FACTOR", 1 January 2014 (2014-01-01) *

Also Published As

Publication number Publication date
KR20190142330A (ko) 2019-12-26
EP4235179B1 (en) 2025-08-13
JP2020512549A (ja) 2020-04-23
AU2018235021B2 (en) 2024-07-11
CA3054915A1 (en) 2018-09-20
EP4235179C0 (en) 2025-08-13
EP4235179A2 (en) 2023-08-30
EP3596467B1 (en) 2023-09-27
IL269315A (en) 2019-11-28
EP4235179A3 (en) 2023-11-15
US12123877B2 (en) 2024-10-22
US20250027946A1 (en) 2025-01-23
KR102583603B1 (ko) 2023-10-05
WO2018167312A1 (en) 2018-09-20
JP7278595B2 (ja) 2023-05-22
EP3596467C0 (en) 2023-09-27
EP3596467A1 (en) 2020-01-22
US20210190787A1 (en) 2021-06-24
IL269315B1 (en) 2025-01-01
AU2018235021A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
US20250027946A1 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
JP6730996B2 (ja) 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
CN110573180B (zh) 癌症治疗用药物组合物
Gubin et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
EP3634584B1 (en) Tumor-infiltrating t-cells for use in the treatment of cancer
TW202019480A (zh) 新穎lilrb4抗體及其用途
US20100143927A1 (en) Methods and Assays for Measuring p95 and/or p95 in a Sample and Antibodies Specific for p95
SG194500A1 (en) Bcma-based stratification and therapy for multiple myeloma patients
JP2021527082A (ja) 新規な免疫チェックポイント阻害剤
GB2546213A (en) Method of isolating circulating tumor cells
CA2990520C (en) Methods for detecting tissue infiltrating nk cells
CN103492582A (zh) 用于测定HE4a的组合物和方法
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
JP2011516840A (ja) 可溶性ｃｄ２００に関するアッセイ法
US20240418722A1 (en) Methods and kits for diagnosing cancer and predicting response to treatment based on cenp-a labelling
WO2020081714A1 (en) Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases
EP4605752A1 (en) Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
WO2017023971A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2016201199A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors